A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy.
Antimicrob Agents Chemother
; 68(1): e0059823, 2024 Jan 10.
Article
en En
| MEDLINE
| ID: mdl-38047751
ABSTRACT
Shiga toxin-producing Escherichia coli infections are difficult to treat due to the risk of antibiotic-induced stress upregulating the production of toxins, medical treatment is consequently limited to supportive care to prevent the development of hemolytic uremic syndrome (HUS). Here, we introduce a potentially therapeutic humanized mouse monoclonal antibody (Hu-mAb 2-5) targeting Stx2a, the most common Shiga toxin subtype identified from outbreaks. We demonstrate that Hu-mAb 2-5 has low immunogenicity in healthy adults ex vivo and high neutralizing efficacy in vivo, protecting mice from mortality and HUS-related tissue damage.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Infecciones por Escherichia coli
/
Escherichia coli Shiga-Toxigénica
/
Síndrome Hemolítico-Urémico
Límite:
Adult
/
Animals
/
Humans
Idioma:
En
Revista:
Antimicrob Agents Chemother
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos